Certificate of Analysis · Lot release · Issued for Epic Wholesalers LLC -dba-Epic Peptides Lab
AICAR 50 mg Pen
Lot PL-2610-010 · Solution · Label claim 50 mg/mL
Tested in-house by PrymaLab
In-house analytical result, not an independent third-party test
Lot / batch number
PL-2610-010
Date made
2026-10-01
Date of analysis
2026-10-02
Date issued
2026-10-16
Retest / expiry
2028-10-01
Units in lot / sampled
312 / 2
Storage
—
Certificate type
Lot COA, 2 pages
Compound
AICAR
Acadesine; 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; nucleoside, not a peptide
CAS number
2627-69-2
Molecular formula
C9H14N4O5
Theoretical mass (avg.)
258.23 Da
Structure
Purity · RP-HPLC, area %
99.81%
Specification ≥ 99.0% • main peak at 6.14 min
Identity · Observed Mass
258.22 Da
Theoretical 258.23 Da • −0.01 Da (39 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
Test
Method
Specification
Result
Conclusion
Identity (mass)
LC-MS, ESI positive
Theoretical ± 1.0 Da
258.22 Da
PASS
Purity
RP-HPLC, UV 254–306 nm, area%
≥ 99.0%
99.81%
PASS
Largest impurity
RP-HPLC, area%
≤ 1.0%
0.09% (RT 8.30)
PASS
Assay (label claim)
Assay vs label claim
47.5–52.5 mg/mL
50.61 mg/mL
PASS
Bacterial endotoxin
LAL, kinetic
≤ 5.0 EU/mg
0.432 EU/mg
PASS
Sterility
USP <71>, 14-day
No growth
No growth
PASS
1HPLC chromatogram
Data file: PL-2610-010-HPLC.raw · Column C18, 150 × 4.6 mm · UV 254–306 nm
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-010-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · continued
AICAR 50 mg Pen · Lot PL-2610-010 · Certificate PL-26-00132
Lot PL-2610-010
Method, peak table and approval
2HPLC method · PL-2610-010-HPLC.raw
Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
254–306 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL
3Gradient program
Time (min)
% A
% B
0.0
95
5
25.0
5
95
4Peak table
Peak
RT (min)
Area
Area %
1
5.10 †
—
0.06
2
6.14
—
99.81
3
7.00 †
—
0.04
4
8.30 †
—
0.09
Total
—
100.00
Peaks: 1 unidentified impurity; 2 main peak (AICAR); 3 unidentified impurity; 4 unidentified impurity · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.
5Identity by mass spectrometry
Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (ion)
259.24 [M+H]+
Deconvoluted Mass
258.22 Da
Theoretical Mass
258.23 Da
Difference
−0.01 Da (39 ppm)
Data File
PL-2610-010-MS.d
Acceptance
Within ± 1.0 Da
6Additional tests
Test
Performed by
Date
Report / file
Assay vs label claim
PrymaLab Analytical
2026-10-02
—
Endotoxin (LAL, kinetic)
PrymaLab Analytical
2026-10-02
—
Sterility (USP <71>, day-14 read-out)
PrymaLab Analytical
2026-10-16
—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.
7Review and approval
D. Reynolds Analyst · performed the testing Date: 2026-10-16
S. Calloway Reviewer · checked against raw data Date: 2026-10-16
M. Phelps Lab Director · approved for release Date: 2026-10-16
